• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Wednesday, February 8, 2023
SLC Metro News
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
No Result
View All Result
Home Travel

Omicron Discovered For The First Time In Boostered Patients – The Germany Eye

omicron-discovered-for-the-first-time-in-boostered-patients-–-the-germany-eye
Share on FacebookShare on Twitter

Image by Alexandra KochA group of seven Germans aged 25 to 39 have contracted the Omicron variant of the coronavirus in South Africa, although all have already received their booster vaccination. Wolfgang Preiser, a member of the research consortium that discovered the variant, told the Tagespiegel newspaper.

“We are seeing a lot of breakthrough infections right now. What we didn’t know is that even the booster vaccination with Biontech/Pfizer doesn’t prevent that,” Preiser told the Tagespiegel newspaper. These infections are the first reported breakthrough infections with the Omicron variant in people who have already received their booster vaccinations.

“Of course, this should not be misunderstood that vaccination does not help. On the contrary, it just shows that even the best possible vaccination is obviously not enough to prevent infection – which we already suspected,” Preiser said.

According to a study Preiser and his colleagues published on the case Thursday, the travel group became infected as early as late November or early December.

All seven had received at least two of their three vaccinations with an mRNA vaccine. Six of them received the Biontech vaccine as their booster, and one received the Moderna vaccine. Six individuals are under 30 years old and one individual is 39 years old.

The individuals received these vaccines in this order:

  • Persons 1 through 5: Biontech, Biontech, Biontech.
  • Person 6: Biontech, Biontech, Moderna
  • Individual 7: Astrazeneca, Biontech, Biontech

Booster vaccinations were administered to subjects between five and ten months after the second vaccinations. The booster vaccinations were at least one month, but no more than two months, the study says. Thus, the affected individuals were among the very early vaccinated in Germany.

None of the seven infected individuals had relevant pre-existing conditions, according to the study, and none had previously tested positive. Four of them were doing medical internships at various local hospitals, and the other three were on vacation. They all tested negative when they arrived in South Africa in the first half of November.

As the seven-day incidence increased significantly in the Western Cape province where they were staying, the seven individuals also developed mild symptoms that began between Nov. 30 and Dec. 2. After testing positive, all individuals went into home quarantine and kept a symptom diary.

During the quarantine, individuals had common Covid 19 symptoms. The most common symptoms were sore throat, fatigue, headache, but dry cough, chest and sinus pressure, rhinitis, and nausea were also reported. One person had night sweats, and another reported a temporary odor and taste disturbances.

The antibody level exhibited by the subjects was at a similar level to four weeks after the second vaccination. In contrast, the viral load of the seven individuals is reported in the study to be higher on average than it was for infections with the original Sars Cov-2 variant from Wuhan, the wild type. However, the study authors note that these are preliminary figures.

However, at 10h7, the omicron variant achieved lower viral loads than the alpha variant in the cases from South Africa four days after symptom onset. According to measurements by the Christian Drostens research group at the Charité, the alpha variant can reach viral loads of 10h8 four days after the onset of symptoms.

None of the seven Germans had to deal with a severe course of the infection. “Of course, you can say now: these are young people anyway. But you can already assume that at least a severe course is prevented,” Preiser said. This conclusion is also supported by the first data from a Biontech study, company CEO Ugur Sahin announced on Wednesday.

Breakthroughs show: The adapted vaccine is needed

Biontech and Pfizer had said Wednesday that, according to their laboratory study, a booster vaccination neutralized the Omicron variant, while the variant could breakthrough vaccine protection after only two vaccinations.The third vaccination allowed the antibody level to increase 25-fold compared to two vaccinations. This level provides a high level of protection against infection with all known virus variants, the companies explained.

On the one hand, the booster breakthroughs in South Africa that have now become public are a setback. But they also show what the companies have already announced: that an adapted vaccine is needed. Biontech and Pfizer expect to have that adapted vaccine ready by the end of March.

As Biontech CEO Sahin explained in an interview with Der Spiegel on Thursday, the decision has not yet been finalized on whether an Omicron vaccine will be produced. Sahin affirmed that in his opinion, current vaccines can still protect well against severe disease. Sahin also brought a timely fourth vaccination into play, then with the new vaccine for the variant.Until then, Wolfgang Preiser explained, booster vaccination is the only thing that will help against Omicron. “But you have to be aware that even that doesn’t prevent infection 100 percent. In other words, you have to keep taking precautions.”

Image by Alexandra Koch

SLC Metro News

© 2021 SLC Metro News

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 SLC Metro News

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT